The Lancet Healthy Longevity

Background Evidence on frailty progression following severe infections is limited. We compared rates of transition to greater frailty or death between adults with and without severe infection in England. Methods We conducted a matched-cohort study among adults aged [≥]65 years (1,452,117: median age 76 years, 45% male) in Clinical Practice Research Datalink Aurum (2006-2019). Adults with severe infection (hospitalised primarily due to infection) were matched on calendar time to individuals without severe infection on age, sex, and primary care practice. The admission date was used as index date and same was assigned to matched unexposed adults. We measured frailty using Electronic Frailty Index, a proportion of 36 health deficits in validated categories (Fit 0-0.12, Mild >0.12-0.24, Moderate >0.24-0.36, Severe >0.36). In a time-varying Markov multistate model, we focused on forward transitions from baseline or intermediate frailty states to higher states or death. For each transition, we used Cox regression to estimate cause-specific transition hazard ratios (HR) with 95% confidence intervals (CIs), comparing adults with and without severe infection. We adjusted for baseline frailty score, age, sex, deprivation, harmful alcohol use, smoking, and primary care infection history 5 years before index date. We estimated state occupancy probabilities, and expected length of stay (ELOS) in each state at year five among adults with and without severe infection. We explored effect modification by infection type. Results Across all transitions, severe infection was associated with higher adjusted hazards of transitioning to worsening frailty or death, HR, 95% CI: (fit to: mild[1.56, 1.54-1.58], moderate[2.51, 1.79-3.51], death[4.57, 4.50-4.65]; mild to: moderate[1.52, 1.50-1.53], severe[1.90, 1.43-2.52], death[2.67, 2.64-2.70]; moderate to: severe[1.40, 1.38-1.42], death[1.87, 1.85-1.90]; severe to death[1.48, 1.46-1.50]). Transition hazard ratios were strongest for lower respiratory tract infections, followed by sepsis, urinary tract infections, meningitis/encephalitis, gastroenteritis, and skin and soft tissue infections. At five years, adults with severe infection had higher probabilities of transitioning to greater frailty or death across all transitions and lower ELOS in each frailty state than those without severe infection. Interpretation Severe infections may accelerate frailty deterioration in older age. Prevention through vaccination, early detection, and prompt management may help mitigate this decline.

Background: Existing electronic frailty indices (eFI) are typically based on structured data and designed for older adults. We developed an eFI that integrates structured and unstructured electronic health records (EHRs) across adulthood and assessed its longitudinal trajectories and associations with adverse outcomes. Methods: We used longitudinal EHR data from 193629 individuals aged 35-103 in the Wellbeing Services County of Central Finland (2010-2023) and constructed a 53-item eFI including diagnosis codes, laboratory tests and items extracted from free-text clinical notes using deep-learning-based natural language processing. Associations with all-cause mortality, severe infections, fractures, and healthcare utilization were assessed using Cox and count models. Predictive performance was compared with Hospital Frailty Risk Score (HFRS) and Charlson Comorbidity Index (CCI). Findings: eFI trajectories accelerated notably from age 65 onwards. Using the eFI as a categorical variable, severe frailty was associated with higher risks of mortality (hazard ratio [HR] 7.31, 95% confidence interval [CI] 6.83-7.83), severe infections (HR 9.22, 95%CI 8.52-9.98), fractures (HR 2.75, 95%CI 2.52-3.01) and increased healthcare utilization (odds ratio [OR] 3.15, 95%CI 2.96-3.35) compared with non-frail. The risks were relatively greater in younger age groups and persisted when using the continuous eFI restricted to non-frail individuals. Across all outcomes, the eFI showed greater model discrimination than HFRS and CCI. Interpretation: An eFI using structured and unstructured EHR data improves risk stratification even in younger adults and at very low levels of frailty. Funding: Research Council of Finland, Instrumentarium Science Foundation, Sigrid Juselius Foundation and Samfundet Folkhalsan.

Abstract Background Persistent pain in later life is associated with functional decline. Identifying resources associated with preserved daily function may broaden pain research beyond symptom burden alone. Objective To examine six prespecified resource indicators-physical activity, depressive symptoms, recall performance, current partner status, education and wealth-in relation to subsequent maintenance of independence in activities of daily living (ADL). Methods This longitudinal observational study analysed adults aged 50 years or older with pain at both the initial and baseline assessments in the Health and Retirement Study (HRS), the English Longitudinal Study of Ageing (ELSA) and the Survey of Health, Ageing and Retirement in Europe (SHARE). ADL maintenance was defined as no difficulty in all five prespecified ADL activities at baseline and no difficulty in all five at follow-up. Indicator-specific risk ratios were estimated using modified Poisson regression with robust variance and pooled using random-effects meta-analysis. The six meta-analysis P values were adjusted using the Holm procedure. Each indicator used a separate complete-case sample; no common six- indicators sample was constructed. Results The descriptive samples comprised 8,279 HRS person-windows contributed by 4,688 unique participants, 1,200 ELSA participants and 6,995 SHARE participants; indicator-specific denominators varied. Physical activity was associated with a higher probability of ADL maintenance across all three cohorts (pooled risk ratio, 1.145; 95% CI, 1.097-1.195; P = .005; Holm-adjusted P = .032) and was the only prespecified hypothesis to meet the Holm-adjusted criterion. The other five hypotheses did not meet this criterion; failure to do so should not be interpreted as evidence that the corresponding associations were absent. Several of these pooled estimates showed substantial heterogeneity. Conclusions Among older adults with persistent pain, physical activity was associated with a higher probability of ADL maintenance, and the physical activity hypothesis was the only one of the six prespecified hypotheses to meet the Holm-adjusted criterion in the three-cohort meta-analysis. These observational findings support further study of physical activity and functional maintenance but do not establish causal benefit.

Importance: Preclinical and human observational studies suggest that metformin may decrease age-related pathology, including frailty. Objective: Determine whether metformin reduces frailty progression and biological age in older adults with glucose intolerance, a population at increased risk of becoming frail. Design, Setting and Participants: Randomized, double-blind, placebo-controlled trial of metformin in 145 non-frail or pre-frail older adults. Participants (72 +/-5 years, 48% female, 94% White, 35% Hispanic) were randomized to metformin vs. placebo for two years. Main Outcomes and Measures: Effect on frailty was primarily determined using generalized estimating equations by change in the Fried frailty phenotype score (based on weight loss, exhaustion, physical activity, gait speed, and grip strength). Because metformin can cause significant weight loss, effects on the Fried score were assessed with and without the weight loss criterion. Frailty also was assessed by change in the frailty index (composite of 95 deficits). Biological age was estimated by DNA methylation-based epigenetic clocks in blood. Results: Metformin led to a non-linear response in the Fried score rate of change, with an upward trajectory in year 1 (0.72 +/-0.22 per year vs. placebo, p=0.0011) and stabilization in year 2 (-0.33 +/-0.17 per year vs. placebo, p=0.056). Metformin led to more weight loss than placebo (-5.7 +/-5.2 vs. -2.3 +/-5.4 kg, p=0.0002); thus, when assessing effect on Fried score without the weight loss criterion, no difference was observed, indicating that weight loss in year 1 accounted for the change in Fried score. Notably, metformin caused a steady improvement in the frailty index (-0.006 +/-0.0026 per year vs. placebo, p=0.0222) that persisted with covariates adjustment including body mass index. Metformin reduced biological age estimated by PC-Horvath2 (-0.40 +/-0.16 per year, p=0.014) and PC-Hannum (-0.33 +/-0.16 per year, p=0.047) clocks. Metformin was well tolerated. Conclusions and Relevance: Metformin halts the progression of the deficit accumulation frailty index and reduces biological age, suggesting potential benefit for extending healthspan. Trial Registration: ClinicalTrials.gov: NCT02570672.

Depression and dementia frequently co-occur, yet sex-specific population-level associations remain unclear. This ecological study examined cross-national relationships between sex-specific depressive disorder incidence and dementia incidence using Institute for Health Metrics and Evaluation data. Analyses included sex-stratified scatterplots, Pearson and Spearman correlations, principal component analysis, partial correlations adjusting for macro-structural factors, and sex-specific multiple linear regression. Visual analyses suggested positive associations in both sexes, but patterns were stronger and more structured among females. Female depressive disorder incidence correlated with dementia incidence in females and males, clustered with structural-development indicators, and remained associated after adjustment. Male depressive disorder incidence showed no significant associations. Overall, depressive disorder incidence was independently associated with dementia incidence among females but not males, supporting a sex-differentiated population level mental health dementia relationship with implications for global womens health and ageing. These findings inform sex-sensitive surveillance, prevention, and policy frameworks in rapidly ageing societies worldwide, particularly within resource-constrained transitional contexts.

Background Population aging is rapidly increasing the burden of multimorbidity and frailty, yet there is limited evidence on how healthy aging policies are implemented across different demographic and health system contexts. Methods We conducted a mixed-methods comparative case study in Spain, Italy, Chile, and Colombia, integrating a Targeted review of policy documents and relevant literature, quantitative indicators, and expert interviews. Results Chile and Colombia showed faster aging dynamics (compound annual growth rates of 4.18% and 4.21%) than Italy (1.96%) and Spain (1.39%), with estimated doubling times of 17 versus 36-50 years. All four countries have established policy frameworks; implementation remains uneven. Key barriers included fragmented services, limited community care, workforce constraints, and misaligned financing. Conclusions The central challenge lies not in the absence of policy frameworks but in their effective implementation. Strengthening primary care, embedding frailty assessment, and improving health-social care integration are key priorities for systems facing rapid demographic transition.

Importance: The ASPREE randomized trial found no overall benefit of low-dose aspirin for disability-free survival among older adults. However, individual estimates in pre-specified subgroups indicated potential benefit among racial and ethnic minoritized participants in the United States (US). Objective: To evaluate whether the effect of low-dose aspirin vs placebo on disability-free survival differed across US Black and Hispanic ASPREE participants using individualized treatment-effect estimation. Design, Setting, and Participants: Post hoc clinical trial analysis of ASPREE, a randomized, double-blind, placebo-controlled clinical trial of daily low-dose aspirin vs placebo. This analysis included US ASPREE participants who self-identified as non-Hispanic Black or Hispanic, were aged 65 years or older, and had complete baseline predictor and outcome data. Interventions: Randomization to daily 100-mg aspirin or placebo. Main Outcomes and Measures: The primary outcome was loss of disability-free survival, defined as death, persistent physical disability, or dementia. Individualized treatment effects were estimated post hoc using a Random Survival Forest X-learner. Heterogeneity was evaluated on the relative scale with Cox proportional hazards models and on the absolute scale with 5-year risk differences. Results: Among 2411 US ASPREE participants, 1270 were included in the Black and Hispanic analytic cohort (897 non-Hispanic Black and 373 Hispanic participants; mean age, 71.8 years). Aspirin was associated with lower risk of disability-free survival loss compared with placebo (hazard ratio [HR], 0.65; 95% CI, 0.45-0.93). In model-derived tertiles, aspirin was associated with lower risk in the greatest predicted-benefit group (HR, 0.36; 95% CI, 0.19-0.71; 5-year absolute risk difference [ARD], -11.1 percentage points; 95% CI, -22.0 to -0.1) but not in the lowest predicted-benefit group (HR, 1.26; 95% CI, 0.70-2.27; ARD, +3.9 percentage points; 95% CI, -5.9 to 13.6). Conclusions and Relevance: In these analyses of US Black and Hispanic ASPREE participants, aspirin effects on disability-free survival appear to be heterogeneous, with benefit concentrated in a subset of participants. Because these findings are from post-hoc models, they should be externally validated before being incorporated into clinical decision-making. Trial Registration: ClinicalTrials.gov Identifier: NCT01038583; https://clinicaltrials.gov/study/NCT01038583

Introduction Frailty is an ageing-related state associated with disability and mortality. Women often experience higher frailty but lower mortality than men, a pattern described as the male-female health-survival paradox. Evidence from low- and middle-income settings is limited. We examined sex differences in frailty trajectories and terminal decline in Mexico. Methods We analysed five waves (2001-2018) of the nationally representative Mexican Health and Aging Study (MHAS) including 12,440 adults ([&ge;]50 years at baseline). Frailty was measured using a 31-deficit frailty index (FI score; 0-1). We used survey-weighted linear mixed-effects models with time interactions, adjusted for sociodemographic, behavioural and health covariates to model sex differences in frailty trajectories. Terminal decline in FI was modelled among those who died using mixed-effects models on the time-to-death scale. Results A total of 12,440 adults aged 50 to 105 years were included, with a mean age of 62.1 years (SD 9.6); 5,698 men (45.8%) and 6,742 women (54.2%). Mean baseline FI was 0.17 (SD 0.12), higher in women than men (0.19 vs 0.16; P<0.001). After adjusting, women had a 0.014 higher mean FI than men at baseline (adjusted mean difference; 95%CI 0.008, 0.020), with difference widening over follow-up, increasing from 0.016 at 2 years to 0.029 at 17 years. Analysis of terminal decline found that accumulation of frailty accelerated in the years preceding death; with results suggesting that women reached death with higher frailty than men (difference 0.029; 95%CI 0.009, 0.048). Conclusion Women experienced higher and more rapidly increasing frailty compared to men and carried a greater frailty burden in the years preceding death. These findings underscore the importance of considering sex differences in frailty trajectories when developing healthy ageing strategies that address the life-course vulnerabilities disproportionately driving frailty accumulation in women in low- and middle-income countries.

Objectives: To estimate hyperlipidemia medication order prevalence and associated variables in U.S. skilled nursing facility (SNF) residents. Design: Retrospective, observational study. Setting and Participants: Electronic Health Record data from 447,080 SNF residents with a hyperlipidemia diagnosis identified in PointClickCare's Life Sciences clinical database (January-April 2025) were reviewed. Methods: The presence and absence of medication orders for hyperlipidemia treatments recommended by the American Heart Association were assessed. Descriptive analyses summarized demographic and clinical characteristics, and a modified Poisson regression model was used to estimate risk ratios for having a medication order, adjusting for demographic, clinical, and facility characteristics. Results: Overall, 83.3% of residents diagnosed with hyperlipidemia had at least one hyperlipidemia medication order. Statins were ordered by 96.2% of active order residents, while other medication classes i.e., omega-3 fatty acids, cholesterol absorption inhibitors, fibrates were less common (<8%). Risk ratios (RRs) for medication orders ranged from 0.87-1.16. Factors most strongly associated with having an order included hypertension medication orders (RR=1.16), unspecified hyperlipidemia diagnosis (RR=1.10), and active diabetes medication orders (RR=1.09); female sex (RR=0.95) and private (0.94) or other (0.87) payer types were associated with a lower likelihood of having an order. Conclusions and Implications: Most residents with a hyperlipidemia diagnosis had an active relevant medication order, but use of non-statin therapies was rare. Differences in treatment patterns by sex and payer type, along with limited uptake of newer agents, warrant further investigation into prescribing practices and access within SNFs.

Diabetic neuropathy is associated with substantial systemic disease burden, but short-term mortality risk among affected intensive care unit (ICU) patients remains difficult to characterize. We evaluated whether temporal information from the first 24 hours of ICU care improves post-landmark mortality prediction beyond severity scores and static clinical summaries. Patients aged > 18 years with diabetic neuropathy were identified in MIMIC-IV v3.1. A 24-hour landmark was used: only patients alive and still hospitalized at 24 hours were included, and the outcome was subsequent in-hospital death. The final cohort included 1,347 patients, including 83 deaths (6.16%). Data were divided into an 80% development set and a locked 20% test set. Feature selection, hyperparameter tuning, calibration, and threshold selection were restricted to development data. Logistic regression, random forest, and XGBoost were evaluated. Random forest had the highest development cross-validated PR-AUC and was selected for interpretation. On the locked test set, random forest achieved an AUROC of 0.851 (95% CI 0.765-0.924), PR-AUC of 0.339, and Brier score of 0.051; XGBoost and logistic regression achieved AUROCs of 0.847 and 0.806. In a post hoc strictly nested analysis, adding temporal predictors increased discrimination across all three algorithms; random-forest AUROC increased from 0.815 with severity and static predictors to 0.870 with the full temporal representation. First-day temporal information therefore showed additional prognostic value, but external validation is required before clinical use.

Long COVID (LC) affects millions of individuals worldwide, particularly those with preexisting comorbidities. However, whether these comorbidities should be defined before SARS-CoV-2 infection or before LC diagnosis remains unresolved, and this methodological choice may substantially bias estimates of comorbidity-associated LC risk. In addition, most previous studies were conducted during earlier phases of the pandemic and relied on relatively small or geographically restricted cohorts, limiting understanding of temporal trends and population disparities in LC risk. Leveraging Electronic Health Records (EHR) from 6,130,413 adults with documented COVID-19 across 49 U.S. states in the National COVID Cohort Collaborative (N3C) from 2020 to 2024, we evaluated the impact of different comorbidity exposure-window definitions on LC risk estimation. We utilized ensemble cross-fitted double/debiased machine learning to adjust for complex individual- and county-level confounders. Across the 16 major comorbidities evaluated, defining conditions before SARS-CoV-2 infection, rather than before LC diagnosis, yielded 23%--115% higher adjusted attributable risks and 6%--37% higher adjusted relative risks. Additionally, comorbidity-associated risks generally declined from 2020 to 2024, with substantial demographic, socioeconomic, geographic, and multimorbidity-related disparities persisting throughout the study period. These findings identify temporal exposure-window specification as a major source of bias in LC epidemiology. Failure to distinguish preexisting comorbidities from conditions identified during postinfection follow-up can substantially alter estimates of disease burden, the identification of high-risk populations, and the interpretation of temporal and geographic disparities. More broadly, our results highlight how temporal misclassification of exposures in longitudinal EHR studies can distort risk attribution and population-level inference.

Urban nature is increasingly recognized as a determinant of healthy aging. However, research has largely focused on the quantity of greenness rather than biodiversity. Evidence supports an association between biodiversity and mental health, but physical aging evidence is very limited. We examined the longitudinal association between residential bird biodiversity and frailty severity using electronic health records. We conducted a retrospective cohort study of 20,388 adults aged 65 years and older receiving primary care in the Mount Sinai Health System in New York City, contributing 123,103 patient-years of follow-up (2011-2023). Residential bird biodiversity was derived from eBird citizen-science data as a modeled, bias-corrected latent Shannon diversity surface at the census-tract level yearly. Frailty severity was measured annually as the deficit count on the 31-item Veterans Affairs Frailty Index (VA-FI). We estimated associations using a negative binomial generalized additive model adjusted for age, sex, race and ethnicity, insurance, tract-level poverty, and non-Hispanic Black proportion, reporting results as the percent change in expected deficit count. We tested effect modification by age group (65-74, 75-84, over 85 years). Each interquartile range increase in residential bird Shannon diversity was associated with a 1.4% lower expected VA-FI deficit count (95% CI -2.1% to -0.8%). The association was strongest among adults aged 65-74 years (-3.0%, 95% CI -3.9% to -2.1%), attenuated among those aged 75-84 years (-0.8%, 95% CI -1.9% to 0.3%), and no longer evident among those aged 85 and older (+1.6%, 95% CI -0.0% to 3.3%). Greater residential bird biodiversity (reflecting both species richness and evenness) was associated with lower frailty severity, with the largest association in early old age. As a bioindicator of underlying environmental quality shaped by modifiable urban design, bird diversity may point to a avenue for supporting healthy aging in dense cities.

Seasonal Influenza and COVID-19 vaccination programmes are critical for reducing morbidity and mortality in older adults, yet uptake remains uneven across populations. We aimed to profile vaccination attitudes and examine predictors of COVID-19/influenza vaccination uptake among a UK participatory surveillance system - FluSurvey. We analysed FluSurvey data from participants aged [&ge;]65 years who were eligible for both vaccines in the 2023-2024 and 2024-2025 Autumn - Winter seasonal campaigns. Descriptive analyses examined self-reported attitudes to influenza vaccination. Logistic regression examined factors (age, sex, socioeconomic status, education, employment, transport, smoking and chronic conditions) associated with influenza and COVID-19 vaccination uptake in each season, adjusting for confounders. Belonging to a risk group and reducing risk of influenza were frequently reported motivations for influenza vaccination, while building natural immunity and concerns around safety and adverse effects were frequently reported barriers. Individuals vaccinated against COVID-19 were more likely to receive an influenza vaccination (aOR2023-2024=13.90 [9.28-21.17]; aOR2024-2025=8.54 [5.82-12.60]), and vice-versa (aOR2023-2024=13.91 [9.30-21.19]; aOR2024-2025=8.52 [5.81-12.58]). Lower educational attainment was associated with lower odds of COVID-19 vaccination (aOR2023-2024=0.59 [0.45-0.78], aOR2024-2025: 0.56 [0.39-0.79]). Other results were weaker or demonstrated variation by season. Our findings highlight recent attitudes and barriers to influenza and COVID-19 vaccination among the FluSurvey cohort, which may inform approaches to improve vaccination coverage in the population.

Background We examined whether two key housing quality indicators, energy efficiency and household overcrowding, were associated with lower respiratory tract infection (LRTI) hospital admissions in infants. Methods We used a cohort of all singleton births in Scotland 2010-2012, created through linked vital statistics and health data. LRTI admissions were characterised in hospital records. Overcrowding (defined using the national room standard) and median postcode-level energy efficiency were defined using maternal Census and postcode-level Energy Performance Certificate data linked to the cohort, respectively. We used logistic regression to model the odds of at least one infant LRTI admission. Results The cohort included 136,123 infants of whom 4.0% had at least one LRTI admission. Overcrowding was more common among infants of younger mothers and those in rented housing. Energy efficiency was lower among infants of older mothers, living in owner occupied homes, in less deprived areas. Compared with infants living in homes with excess rooms (under-occupied housing), those whose homes were below, or met, the minimum room standard had higher odds of LRTI admission (adjusted odds ratio 1.07, 95% CI 0.98-1.17; 1.10, 95% CI 1.03-1.17, respectively). Postcode-level energy efficiency was not associated with LRTI admission odds. Conclusion Overcrowding was more common in socioeconomically disadvantaged households and associated with increased risk of LRTI admission in infancy. Lower energy efficiency was associated with factors commonly linked to socioeconomic advantage and was not associated with LRTI admissions. Improving access to housing with adequate living space may reduce the burden of LRTIs in early life.

Objectives: To evaluate rates of pharmacological hypertension orders and identify resident- and facility-level predictors of pharmacologic care among skilled nursing facility (SNF) residents in the United States. Design: Retrospective, observational study. Setting and Participants: Electronic Health Record data from 1,285,062 long-term care residents in PointClickCare's Life Sciences database in facility on April 30, 2025 were reviewed, and 553,519 SNF residents with a documented hypertension diagnosis were identified. Methods: The presence and absence of medication orders for antihypertensive treatment recommended by the International Society of Hypertension was assessed. Descriptive analyses summarized demographic and clinical characteristics, and a modified Poisson regression model was used to estimate risk ratios (RRs) for having a medication order, adjusting for demographic, clinical, and facility characteristics. Results: Overall, 87.7% of residents diagnosed with hypertension had at least one antihypertensive medication order. Calcium channel blockers (44.3%) and beta blockers (43.5%) were the most frequently used classes. RRs ranged from 0.91 to 1.09. Higher likelihoods of antihypertensive orders were observed among residents prescribed hyperlipidemia and diabetes medication (RR = 1.09 and 1.05, respectively), while lower likelihoods of treatment were observed for other payer types (RR = 0.91), diabetes diagnoses (RR = 0.95), and hyperlipidemia diagnoses (RR = 0.98). Conclusions and Implications: Most residents with hypertension had orders for recommended pharmacologic therapy, although important gaps and disparities remain. The predominance of certain medication classes and persistent differences by comorbidity and facility type underscore the need for targeted strategies to improve equitable prescribing and access to evidence-based hypertension management in SNF settings.

Background Whether adiposity is protective against or detrimental to skeletal muscle health in older adults remains unresolved. The conflicting associations between adiposity and sarcopenia, ranging from apparently protective to harmful effects, have been described as the "obesity paradox". We investigated whether this paradox could be explained by heterogeneity in muscle functional capacity, hypothesising that the adiposity-sarcopenia relationship is modified by relative grip strength (RGS). Methods We conducted a cross-sectional analysis of the China Health and Retirement Longitudinal Study (CHARLS; n=15,701), with independent external validation in the US National Health and Nutrition Examination Survey (NHANES; n=10,730). RGS was defined as maximal grip strength divided by body weight. To minimise selective reporting, we performed a prespecified systematic screen of 536 interaction terms derived from 10 anthropometric exposures, 33 functional modifiers, and two sarcopenia outcomes. Core findings were evaluated through cross-metric and cross-outcome replication, sensitivity analyses addressing concerns regarding diagnostic circularity and mathematical coupling, and mediation analyses exploring potential biological pathways. Findings Among 536 tested interactions, 36 met the Bonferroni-corrected significance threshold, and 32 (89%) involved grip-related modifiers. The interaction between waist circumference and RGS for possible sarcopenia was highly significant (p=6.19 x 10(-24)). Stratified analyses showed that higher adiposity was associated with lower odds of sarcopenia, but the magnitude of this association differed substantially by RGS. For BMI, the inverse association was approximately 10-fold stronger among individuals with high RGS than among those with low RGS (OR 0.64, 95% CI 0.60-0.69 vs OR 0.97, 95% CI 0.96-0.98). Similar effect modification patterns were observed across four anthropometric measures and both sarcopenia outcomes, and were independently replicated in NHANES (p<1.0 x 10(-16)). The interaction was no longer evident after restricting analyses to participants with preserved grip strength (p=0.65). Mediation analyses suggested that the association was predominantly direct, with triglycerides accounting for 10.5% of the total effect. Interpretation The association between adiposity and sarcopenia is strongly modified by relative grip strength and appears to be concentrated among individuals with preserved muscle functional capacity. These findings provide a potential explanation for heterogeneity underlying the obesity paradox and suggest that integrating grip strength assessment into adiposity evaluation may improve risk stratification for sarcopenia in older adults.

COVID-19 vaccination helped change the course of the pandemic and remains critical for protecting high-risk groups. We analyzed data submitted to WHO to describe COVID-19 vaccination coverage during the emergency period from 2021-2023 and annual uptake in 2024, the first post-emergency calendar year after the Public Health Emergency of International Concern designation was lifted. By end-2023, global complete primary series coverage reached 65% in the total population, 82% among older adults, and 91% among health and care workers (HCWs), across reporting countries. Booster coverage was lower, at 33%, 60%, and 69%, respectively. Across indicators, disparities by country income group and region emerged early and persisted through 2024. In 2024, vaccination of older adults and HCWs was limited and heterogeneous. These findings underscore the need for stronger, sustainably financed adult immunization platforms and associated monitoring systems to enhance life-course vaccination benefits and to support future outbreak, epidemic, and pandemic responses.

Background: Polypharmacy is an escalating global health challenge, yet longitudinal evidence regarding its impact on mortality in Latin American aging populations remains limited. This study evaluated the association between medication burden and all cause mortality among community dwelling older adults in a rapidly aging region of Colombia. Methods: A longitudinal analysis was conducted using a sub-cohort of 4,110 participants (aged 60 years or more) from the SABE Colombia survey (Antioquia, Caldas, Risaralda, and Quindio). Vital status was adjudicated via the National Health System Resources Administrator (ADRES) database over a mean follow-up of 79 months. Polypharmacy was defined as the concurrent use of 5 9 medications and excessive polypharmacy as 10 or more. Extended Cox proportional hazards models were employed to estimate hazard ratios (HR), adjusting for sociodemographic factors, multimorbidity, and functional dependency. Results: At baseline, 20.2% of participants presented polypharmacy and 2.1% excessive polypharmacy. A total of 1,092 deaths (26.6%) were recorded during follow-up. After multivariable adjustment, both moderate polypharmacy (HR 1.17; 95% CI 1.02 - 1.31; p=0.029) and excessive polypharmacy (HR 1.82; 95% CI 1.34 - 2.47; p<0.001) were identified as independent predictors of mortality. Notably, the risk was markedly higher at the 10 or more medication threshold, suggesting a non-linear relationship between pharmacological burden and survival. Conclusions: Polypharmacy is a significant and independent predictor of mortality in Colombian older adults, with the risk nearly doubling in cases of excessive medication use. These findings underscore the urgent need for structured medication review and deprescribing interventions tailored to resource-constrained healthcare systems to mitigate the risks associated with high pharmacological accumulation. Keywords: Polypharmacy, Aged, Mortality, Longitudinal, Colombia.

Evidence on vaccine effectiveness (VE) of 2025-26 COVID-19 vaccines is limited. We estimated VE of BNT162b2 LP.8.1-adapted vaccine among non-immunocompromised adults [&ge;]65 years through December 2025 using linked claims and immunization registry data from two U.S. states. VE against COVID-19-related ED/UC encounters was 48% (95% CI:19, 66).

In early sepsis the direction in which blood immune-cell transcriptional programmes move may carry prognostic information beyond a single baseline measurement, but whether such trajectory associations survive independent testing is unknown. We scored five immune modules, frozen before analysis, in three public longitudinal whole-blood microarray sepsis cohorts and fitted a logistic model ladder fixed in advance to the change per 24 hours in the two cohorts with mortality data (82 patients, 24 deaths), pooling by inverse-variance fixed-effect meta-analysis with Benjamini-Hochberg control. No association survived correction for multiple testing. The two leading signals were a rising CD4/NK lymphocyte trajectory associated with lower mortality (pooled odds ratio 0.53, 95% confidence interval 0.31 to 0.90) and a rising emergency-granulopoiesis trajectory associated with higher mortality (1.60, 0.92 to 2.79), both per one standard deviation. We then tested both in an independent transcriptomic cohort with serial sampling (63 patients, 15 deaths), scored by the identical frozen method, and against their cell-count analogues in an intensive-care database of 12,607 adults meeting Sepsis-3 criteria, of whom 744 to 4,206 had the serial measurements each analogue required. Independent testing separated the two signals, in the order opposite to the one discovery had suggested. The emergency-granulopoiesis association was reproduced in direction and effect size without reaching conventional significance on its own (validation odds ratio 1.72, 0.92 to 3.20, p=0.088; pooled 1.65, 1.09 to 2.50), was positive in all nine sensitivity analyses, each fixed before the estimates were examined, and was supported by two of its three analogues, including the neutrophil-to-lymphocyte ratio (1.31, 1.20 to 1.42). The CD4/NK association did not reproduce (1.06, 0.59 to 1.89), was null in the window most favourable to it, and received no support from an analogue well powered to detect the discovery effect. The discovery signal that looked most consistent failed independent testing.